Targeting a specific protein to help treat multiple sclerosis
Targeting OCA-B in multiple sclerosis
This study is looking at a protein called OCA-B to find new ways to treat multiple sclerosis (MS) by understanding how it affects T cells, which are important for your immune system, with the hope of creating therapies that can slow down MS while keeping your immune system healthy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11010366 on NIH RePORTER |
What this research studies
This research focuses on developing new treatments for multiple sclerosis (MS) by targeting a protein called OCA-B, which plays a crucial role in regulating immune responses. The study investigates how OCA-B influences T cells, which are key players in MS, particularly in their ability to remember past infections and respond to them. By understanding the mechanisms behind OCA-B's function, the research aims to create therapies that can block MS progression while preserving the immune system's beneficial functions. Patients may benefit from insights into how their immune system can be modulated to prevent or reduce MS symptoms.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple sclerosis who are experiencing symptoms related to the disease.
Not a fit: Patients with other autoimmune conditions unrelated to multiple sclerosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that effectively manage multiple sclerosis without compromising the immune system.
How similar studies have performed: Previous research has shown promise in targeting immune pathways in autoimmune diseases, suggesting that this approach could yield significant advancements.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Tantin, Dean — University of Utah
- Study coordinator: Tantin, Dean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.